FOXP3 and cancer: The presence of FOXP3+ tumor-infiltrating lymphocytes (TILs) has been reported to be associated with poor clinical outcome in a variety of cancer types, including prostatic, lung, hepatocellular and renal cell carcinomas [6]-[10], indicating that cancer patients may benefit from blocking the capacity of tumor cells to recruit Tregs.